There is one clinical trial.
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19. This protocol CORIMUNO19-COAG will evaluate the efficacy and safety of active anticoagulation using heparin: Tinzaparin (INNOHEP®) or unfractionated heparin (Calciparine®, Héparine Sodique Choay®) in COVID-19 patients hospitalized in conventional or intensive care units. It will use a phase 2 randomized open-label multicentre clinical trial, where patients will be randomly allocated to anticoagulation versus Standard of Care.
Description: group 1Measure: Survival without ventilation (VNI or mechanical ventilation) Time: day 14
Description: group 2Measure: ventilator free survival Time: day 28
Description: range from 0 (healthy) to 10 (death) values below or equal to 5 correspond to the absence of any oxygen supply beside nasal or facial maskMeasure: World Health Organisation(WHO) progression scale ≤5 Time: day 4
Description: range from 0 (healthy) to 10 (death)Measure: World Health Organisation(WHO) progression scale Time: day 4, 7 and 14
Description: according to Acute Kidney Injury (AKIN) classification systemMeasure: rate of acute kidney injury Time: day 28
Description: confirmed by objective testingMeasure: rate of clinically overt pulmonary embolism or proximal deep vein thrombosis Time: day 14 and day 90
Description: confirmed by objective testingMeasure: Rate of clinically overt arterial thrombosis Time: day 14 and day 90
Description: as a thrombus extending from the catheter into the lumen of the deep vein where the catheter is inserted diagnosed with radiologic imaging in case of a clinical suspicion of upper/lower limb DVT or pulmonary embolism or compulsory catheter removalMeasure: Rate of central venous catheter-related deep vein thrombosis (CVC-DVT) Time: day 28